Genmab A/S (GE9) Stock Forecast & Price Target

Compare

14 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GE9 Analyst Ratings

Moderate Buy

5 Buy

3 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Genmab

A/S

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GE9 Stock 12 Month Forecast

Average Price Target

€299.25

▲(19.94% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is €299.25 with a high forecast of €368.09 and a low forecast of €187.39. The average price target represents a 19.94% change from the last price of €249.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"173":"€173","222":"€222","271":"€271","320":"€320","369":"€369"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":368.093,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€368.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":299.2484546666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€299.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":187.3928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€187.39</span>\n  </div></div>","useHTML":true}}],"tickPositions":[173,222,271,320,369],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,280.3,287.0533076923077,293.8066153846154,300.5599230769231,307.31323076923076,314.06653846153847,320.8198461538462,327.57315384615384,334.32646153846156,341.0797692307692,347.83307692307693,354.58638461538465,361.3396923076923,{"y":368.093,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,280.3,281.7575734358974,283.21514687179484,284.6727203076923,286.13029374358973,287.58786717948715,289.04544061538456,290.50301405128204,291.96058748717945,293.41816092307687,294.8757343589743,296.33330779487176,297.7908812307692,{"y":299.2484546666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,280.3,273.1532923076923,266.0065846153846,258.8598769230769,251.71316923076924,244.56646153846154,237.41975384615384,230.27304615384617,223.12633846153847,215.97963076923077,208.83292307692307,201.68621538461537,194.53950769230767,{"y":187.3928,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":190.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":280.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€368.09

Average Price Target€299.25

Lowest Price Target€187.39

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Justin Smith

Bernstein

€135.86→€187.39

Sell

-24.89%

Downside

Reiterated

02/23/26

Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks

James Gordon CFA

Barclays

€334.63

Buy

34.12%

Upside

Reiterated

02/23/26

Genmab A/S (0MGB) Receives a Buy from Barclays

Rajan Sharma

Goldman Sachs

€240→€237.05

Hold

-4.99%

Downside

Reiterated

02/18/26

Goldman Sachs Keeps Their Hold Rating on Genmab A/S (0MGB)

Charlie Haywood

Bank of America Securities

€334.63

Buy

34.12%

Upside

Reiterated

02/18/26

Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside

Benjamin Jackson CFA

Jefferies

€354.71

Buy

42.17%

Upside

Initiated

02/16/26

Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target

Xian Deng

UBS

€368.09

Buy

47.53%

Upside

Reiterated

01/19/26

Genmab A/S (0MGB) Gets a Buy from UBS

Jon Berggren

Kepler Capital

€281.09

Hold

12.66%

Upside

Reiterated

01/19/26

Kepler Capital Sticks to Its Hold Rating for Genmab A/S (0MGB)

Emmanuel Papadakis

Deutsche Bank

€267.7→€321.24

Buy

28.76%

Upside

Reiterated

01/06/26

Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche BankGenmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank

Zain Ebrahim

J.P. Morgan

€220.86→€274.4

Hold

9.98%

Upside

Reiterated

12/08/25

Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorganGenmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/07/25

Guggenheim Keeps Their Hold Rating on Genmab A/S (0MGB)

Alistair Campbell

RBC Capital

€307.86→€267.7

Buy

7.30%

Upside

Reiterated

05/29/25

RBC Capital Remains a Buy on Genmab A/S (0MGB)

Rajesh Kumar

HSBC

€397.54→€266.37

Buy

6.76%

Upside

Reiterated

04/28/25

Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBCGenmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC

Victor Floc'h

Exane BNP Paribas

€187.39→€174.01

Hold

-30.26%

Downside

Reiterated

04/16/25

Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK1,300 at BNP Paribas ExaneBNP Paribas Exane analyst Victor Floch lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK1,300.00 (from DKK1,400.00) while maintaining a Neutral rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Justin Smith

Bernstein

€135.86→€187.39

Sell

-24.89%

Downside

Reiterated

02/23/26

Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks

James Gordon CFA

Barclays

€334.63

Buy

34.12%

Upside

Reiterated

02/23/26

Genmab A/S (0MGB) Receives a Buy from Barclays

Rajan Sharma

Goldman Sachs

€240→€237.05

Hold

-4.99%

Downside

Reiterated

02/18/26

Goldman Sachs Keeps Their Hold Rating on Genmab A/S (0MGB)

Charlie Haywood

Bank of America Securities

€334.63

Buy

34.12%

Upside

Reiterated

02/18/26

Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside

Benjamin Jackson CFA

Jefferies

€354.71

Buy

42.17%

Upside

Initiated

02/16/26

Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target

Xian Deng

UBS

€368.09

Buy

47.53%

Upside

Reiterated

01/19/26

Genmab A/S (0MGB) Gets a Buy from UBS

Jon Berggren

Kepler Capital

€281.09

Hold

12.66%

Upside

Reiterated

01/19/26

Kepler Capital Sticks to Its Hold Rating for Genmab A/S (0MGB)

Emmanuel Papadakis

Deutsche Bank

€267.7→€321.24

Buy

28.76%

Upside

Reiterated

01/06/26

Genmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche BankGenmab price target raised to DKK 2,400 from DKK 2,000 at Deutsche Bank

Zain Ebrahim

J.P. Morgan

€220.86→€274.4

Hold

9.98%

Upside

Reiterated

12/08/25

Genmab price target raised to DKK 2,050 from DKK 1,650 at JPMorganGenmab price target raised to DKK 2,050 from DKK 1,650 at JPMorgan

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

08/07/25

Guggenheim Keeps Their Hold Rating on Genmab A/S (0MGB)

Alistair Campbell

RBC Capital

€307.86→€267.7

Buy

7.30%

Upside

Reiterated

05/29/25

RBC Capital Remains a Buy on Genmab A/S (0MGB)

Rajesh Kumar

HSBC

€397.54→€266.37

Buy

6.76%

Upside

Reiterated

04/28/25

Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBCGenmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC

Victor Floc'h

Exane BNP Paribas

€187.39→€174.01

Hold

-30.26%

Downside

Reiterated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genmab A/S

3 Months

xxx

Success Rate

10/20 ratings generated profit

Average Return

+4.60%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +4.60% per trade.

1 Year

Emmanuel PapadakisDeutsche Bank

Success Rate

12/20 ratings generated profit

Average Return

+10.81%

a rating ―

Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +10.81% per trade.

2 Years

xxx

Success Rate

15/20 ratings generated profit

Average Return

+16.98%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +16.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GE9 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GE9 has received 12 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. GE9 average Analyst price target in the past 3 months is 299.25.

Each month's total comprises the sum of three months' worth of ratings.

GE9 Financial Forecast

GE9 Earnings Forecast

Next quarter’s earnings estimate for GE9 is €1.57 with a range of €0.34 to €3.49. The previous quarter’s EPS was €0.41. GE9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year GE9 has Performed in-line its overall industry.

GE9 Sales Forecast

Next quarter’s sales forecast for GE9 is €768.02M with a range of €693.37M to €852.67M. The previous quarter’s sales results were €908.68M. GE9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year GE9 has Performed in-line its overall industry.

GE9 Stock Forecast FAQ

What is DE:GE9’s average 12-month price target, according to analysts?

Based on analyst ratings, Genmab A/S’s 12-month average price target is 299.25.

What is DE:GE9’s upside potential, based on the analysts’ average price target?

Genmab A/S has 19.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Genmab A/S a Buy, Sell or Hold?

Genmab A/S has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 3 hold ratings and 1 sell ratings.

What is Genmab A/S’s share price target?

The average share price target for Genmab A/S is 299.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €368.09 ,and the lowest forecast is €187.39. The average share price target represents 19.94% Increase from the current price of €249.5.

What do analysts say about Genmab A/S?

Genmab A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Genmab A/S?

To buy shares of DE:GE9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Genmab A/S (GE9) Stock Forecast & Price Target

GE9 Analyst Ratings

GE9 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genmab A/S

GE9 Analyst Recommendation Trends

GE9 Financial Forecast

GE9 Earnings Forecast

GE9 Sales Forecast

GE9 Stock Forecast FAQ

Detailed List of Analyst Forecasts